ETHK Labs Warns of Sharp 2025 Profit Drop Amid Margin Squeeze and Listing Costs

IVD Medical Holding Limited ( (HK:1931) ) has shared an update.

ETHK Labs Inc., a Hong Kong-listed in vitro diagnostics company incorporated in the Cayman Islands, develops and sells IVD products in an increasingly competitive market. The Group is also working toward a proposed dual listing in the United States to broaden its financing channels and back ongoing expansion.

The company has warned that profit attributable to shareholders for 2025 is expected to fall sharply to no more than about RMB42.2 million from RMB260.4 million a year earlier. Management attributes the decline to margin pressure from tougher IVD competition, higher administrative expenses tied to U.S. listing preparations, and increased finance costs from greater borrowings, and has cautioned investors as the figures remain unaudited and subject to adjustment.

The most recent analyst rating on (HK:1931) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.

More about IVD Medical Holding Limited

ETHK Labs Inc., incorporated in the Cayman Islands and listed in Hong Kong, operates in the in vitro diagnostics (IVD) industry. The Group focuses on IVD products and services in a competitive operating environment, and is pursuing a proposed dual listing in the United States to support its business expansion and capital needs.

Average Trading Volume: 4,698,216

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.95B

For a thorough assessment of 1931 stock, go to TipRanks’ Stock Analysis page.